BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

Cara L. Haymaker, Richard C. Wu, Krit Ritthipichai, Chantale Bernatchez, Marie Andrée Forget, Jie Qing Chen, Hui Liu, Ena Wang, Francesco Marincola, Patrick Hwu, Laszlo G. Radvanyi

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8+ T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we further characterized this CD8+BTLA+ TIL subset and their CD8+BTLA counterparts. We found that the CD8+ BTLA+ TILs had an increased response to IL-2, were less-differentiated effector-memory (TEM) cells, and persisted longer in vivo after infusion. In contrast, CD8+BTLA TILs failed to proliferate and expressed genes associated with T-cell deletion/tolerance. Paradoxically, activation of BTLA signaling by its ligand, herpes virus entry mediator (HVEM), inhibited T-cell division and cytokine production, but also activated the Akt/PKB pathway thus protecting CD8+BTLA+ TILs from apoptosis. Our results point to a new role of BTLA as a useful T-cell differentiation marker in ACT and a dual signaling molecule that curtails T-cell activation while also conferring a survival advantage for CD8+ T cells. These attributes may explain our previous observation that BTLA expression on CD8+ TILs correlates with clinical response to adoptive T-cell therapy in metastatic melanoma.

Original languageEnglish
JournalOncoImmunology
Volume4
Issue number8
DOIs
Publication statusPublished - 3 Aug 2015
Externally publishedYes

Fingerprint

Tumor-Infiltrating Lymphocytes
Lymphocyte Subsets
Melanoma
T-Lymphocytes
Survival
Costimulatory and Inhibitory T-Cell Receptors
Cell- and Tissue-Based Therapy
Virus Internalization
Differentiation Antigens
Cell Division

Keywords

  • B- and T-lymphocyte attenuator
  • CD8<sup>+</sup> effector-memory
  • melanoma
  • T cell survival/persistence
  • tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Haymaker, C. L., Wu, R. C., Ritthipichai, K., Bernatchez, C., Forget, M. A., Chen, J. Q., ... Radvanyi, L. G. (2015). BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. OncoImmunology, 4(8). https://doi.org/10.1080/2162402X.2015.1014246

BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. / Haymaker, Cara L.; Wu, Richard C.; Ritthipichai, Krit; Bernatchez, Chantale; Forget, Marie Andrée; Chen, Jie Qing; Liu, Hui; Wang, Ena; Marincola, Francesco; Hwu, Patrick; Radvanyi, Laszlo G.

In: OncoImmunology, Vol. 4, No. 8, 03.08.2015.

Research output: Contribution to journalArticle

Haymaker, CL, Wu, RC, Ritthipichai, K, Bernatchez, C, Forget, MA, Chen, JQ, Liu, H, Wang, E, Marincola, F, Hwu, P & Radvanyi, LG 2015, 'BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties', OncoImmunology, vol. 4, no. 8. https://doi.org/10.1080/2162402X.2015.1014246
Haymaker, Cara L. ; Wu, Richard C. ; Ritthipichai, Krit ; Bernatchez, Chantale ; Forget, Marie Andrée ; Chen, Jie Qing ; Liu, Hui ; Wang, Ena ; Marincola, Francesco ; Hwu, Patrick ; Radvanyi, Laszlo G. / BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. In: OncoImmunology. 2015 ; Vol. 4, No. 8.
@article{f8312aab029742c790be343519709539,
title = "BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties",
abstract = "In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8+ T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we further characterized this CD8+BTLA+ TIL subset and their CD8+BTLA− counterparts. We found that the CD8+ BTLA+ TILs had an increased response to IL-2, were less-differentiated effector-memory (TEM) cells, and persisted longer in vivo after infusion. In contrast, CD8+BTLA− TILs failed to proliferate and expressed genes associated with T-cell deletion/tolerance. Paradoxically, activation of BTLA signaling by its ligand, herpes virus entry mediator (HVEM), inhibited T-cell division and cytokine production, but also activated the Akt/PKB pathway thus protecting CD8+BTLA+ TILs from apoptosis. Our results point to a new role of BTLA as a useful T-cell differentiation marker in ACT and a dual signaling molecule that curtails T-cell activation while also conferring a survival advantage for CD8+ T cells. These attributes may explain our previous observation that BTLA expression on CD8+ TILs correlates with clinical response to adoptive T-cell therapy in metastatic melanoma.",
keywords = "B- and T-lymphocyte attenuator, CD8<sup>+</sup> effector-memory, melanoma, T cell survival/persistence, tumor-infiltrating lymphocytes",
author = "Haymaker, {Cara L.} and Wu, {Richard C.} and Krit Ritthipichai and Chantale Bernatchez and Forget, {Marie Andr{\'e}e} and Chen, {Jie Qing} and Hui Liu and Ena Wang and Francesco Marincola and Patrick Hwu and Radvanyi, {Laszlo G.}",
year = "2015",
month = "8",
day = "3",
doi = "10.1080/2162402X.2015.1014246",
language = "English",
volume = "4",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "8",

}

TY - JOUR

T1 - BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties

AU - Haymaker, Cara L.

AU - Wu, Richard C.

AU - Ritthipichai, Krit

AU - Bernatchez, Chantale

AU - Forget, Marie Andrée

AU - Chen, Jie Qing

AU - Liu, Hui

AU - Wang, Ena

AU - Marincola, Francesco

AU - Hwu, Patrick

AU - Radvanyi, Laszlo G.

PY - 2015/8/3

Y1 - 2015/8/3

N2 - In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8+ T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we further characterized this CD8+BTLA+ TIL subset and their CD8+BTLA− counterparts. We found that the CD8+ BTLA+ TILs had an increased response to IL-2, were less-differentiated effector-memory (TEM) cells, and persisted longer in vivo after infusion. In contrast, CD8+BTLA− TILs failed to proliferate and expressed genes associated with T-cell deletion/tolerance. Paradoxically, activation of BTLA signaling by its ligand, herpes virus entry mediator (HVEM), inhibited T-cell division and cytokine production, but also activated the Akt/PKB pathway thus protecting CD8+BTLA+ TILs from apoptosis. Our results point to a new role of BTLA as a useful T-cell differentiation marker in ACT and a dual signaling molecule that curtails T-cell activation while also conferring a survival advantage for CD8+ T cells. These attributes may explain our previous observation that BTLA expression on CD8+ TILs correlates with clinical response to adoptive T-cell therapy in metastatic melanoma.

AB - In a recent adoptive cell therapy (ACT) clinical trial using autologous tumor-infiltrating lymphocytes (TILs) in patients with metastatic melanoma, we found an association between CD8+ T cells expressing the inhibitory receptor B- and T-lymphocyte attenuator (BTLA) and clinical response. Here, we further characterized this CD8+BTLA+ TIL subset and their CD8+BTLA− counterparts. We found that the CD8+ BTLA+ TILs had an increased response to IL-2, were less-differentiated effector-memory (TEM) cells, and persisted longer in vivo after infusion. In contrast, CD8+BTLA− TILs failed to proliferate and expressed genes associated with T-cell deletion/tolerance. Paradoxically, activation of BTLA signaling by its ligand, herpes virus entry mediator (HVEM), inhibited T-cell division and cytokine production, but also activated the Akt/PKB pathway thus protecting CD8+BTLA+ TILs from apoptosis. Our results point to a new role of BTLA as a useful T-cell differentiation marker in ACT and a dual signaling molecule that curtails T-cell activation while also conferring a survival advantage for CD8+ T cells. These attributes may explain our previous observation that BTLA expression on CD8+ TILs correlates with clinical response to adoptive T-cell therapy in metastatic melanoma.

KW - B- and T-lymphocyte attenuator

KW - CD8<sup>+</sup> effector-memory

KW - melanoma

KW - T cell survival/persistence

KW - tumor-infiltrating lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=84940492696&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940492696&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1014246

DO - 10.1080/2162402X.2015.1014246

M3 - Article

VL - 4

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 8

ER -